BIOCYTOGEN-B(02315): IDEAYA nominates B7H3/PTK7 bispecific ADC (IDE034) as a development candidate with potential first-in-class isomerase inhibitor payload and dual specificity.

BIOCYTOGEN-B (02315) announces that IDEAYA Biosciences, Inc. (NASDAQ: IDYA) ("IDEAYA"), a precision oncology company dedicated to discovering and developing targeted therapies, has exercised its option to obtain global exclusive rights to BCG034 (IDE034), a bispecific antibody-drug conjugate (BsADC) targeting B7H3/PTK7 with potential for first-in-class benefits, and has nominated this project as a lead candidate for development. Dr. Yulei Shen, Chairman and CEO of BIOCYTOGEN, stated: "We are pleased that IDEAYA has decided to exercise their option to obtain the global exclusive rights to our B7H3/PTK7 BsADC project, IDE034, which integrates our proprietary topology heteromeric enzyme- payload technology. This important milestone in our collaboration further validates the capabilities of our RenLite platform and brings us one step closer to providing impactful treatments for solid tumor patients. We look forward to and support IDEAYA in advancing this project into clinical development." Dr. Michael White, Chief Scientific Officer of IDEAYA Biosciences, said: "We are excited to nominate IDE034 as a lead candidate for development. This first-in-class B7H3/PTK7 topology heteromeric enzyme inhibitor payload BsADC showed significant tumor regression in preclinical models. The high co-expression of B7H3/PTK7 in solid tumors such as lung cancer, colorectal cancer, and head and neck cancer highlights its potential as a monotherapy and in combination with our PARG inhibitor IDE161." IDEAYA plans to submit an Investigational New Drug (IND) application for IDE034 to the US FDA in 2025 to initiate first-in-human trials, following completion of current preclinical and IND-enabling studies. Under the option and license agreement between BIOCYTOGEN and IDEAYA, BIOCYTOGEN will receive upfront and option exercise fees, additional development and regulatory milestone payments, commercial milestone payments, and net sales royalties, totaling up to $406.5 million, including up to $100 million in clinical development and regulatory milestone payments. According to the Human Protein Atlas database, B7H3/PTK7 is co-expressed in various solid tumor types, with co-expression rates of approximately 30% in lung cancer, 46% in colorectal cancer, and 27% in head and neck cancer.